• Aspire Biopharma stockholders held a special meeting on April 10, 2026.
• Shareholders backed a charter amendment authorizing a reverse stock split, with a ratio range of 1-for-5 to 1-for-500 set at board discretion within one year.
• Approval was also granted for issuance of common shares issuable on conversion of Series A Convertible Preferred Stock, including conversion shares above the 19.99% threshold, with a conversion floor price set at 20% of the Minimum Price.
• Investors authorized issuance of 19.99% or more of outstanding common stock under the equity line of credit purchase agreement with Arena Business Solutions Global SPC II, Ltd.
• Shareholders also approved an amendment to increase authorized common shares to 700,000,000, alongside authority to adjourn the meeting if needed to solicit additional proxies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017054), on April 16, 2026, and is solely responsible for the information contained therein.